The Swiss pharma company Novartis ranks in the top 10 of pharma companies, and boasts drugs ranging from Ritalin and Lamisil to clozapine, Diovan and Gilenya. It also owns the generic giant Sandoz. Unlike its competitor, GlaxoSmithKline, Novartis did not offer free flu vaccines during the H1N1 flu epidemic.

In March 2011, Novartis gained FDA approval for Gilenya, its multiple sclerosis drug. The nod came on the heels of a narrower EMA approval, which grants second-line treatment status. According to experts, the drug could be worth $3 billion in annual sales as the first oral MS drug on the market.

Novartis purchased the remaining portion of eye care company Alcon in a $12.9 billion deal at the end of 2010, marking the end of one of the biggest battles in biopharma. Although many analysts predicted heavy layoffs in 2010 from the company, only 1,400 jobs were cut in December 2010, with the disclaimer that more could be on the way as Novartis, like others in the industry, analyzes its efficiency.

Tag:

Novartis

Latest Headlines

Latest Headlines

Novartis sets sights on Philly amid a sweeping CAR-T collaboration

Novartis has leased a sizable outpost in the Philadelphia suburbs, according to a local report, settling into the area as it works with University of Pennsylvania researchers on a promising new approach to treating cancer.

Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug

Amid growing discontent from Big Pharma companies over India's patent-busting policies, generics maker Cipla is petitioning the country's government to revoke 5 patents for Novartis' respiratory drug Indacterol and is launching a low-cost version of the product to boost local access.  

Pfizer beats out Novartis with FDA MenB nod

We have a winner. In a two-horse race to grab the first-ever U.S. approval for a meningitis B vaccine, Pfizer has emerged victorious, nabbing the FDA's blessing Wednesday.

A tale of 'two worlds' for Novartis respiratory launches in U.S. and EU

Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches within and outside the U.S. could end up being worlds apart.

For Novartis' respiratory ambitions, it's a tale of 'two worlds'

Targeting different markets naturally requires using different marketing strategies. But for Novartis, which is aiming to become a major respiratory player, its approaches within and outside the U.S. could end up being worlds apart.

Novartis gets 4% sales lift as 'growth products' make good on their label

Novartis' third-quarter profit may have gotten a large boost from the sale of its Idenix stake to Merck this summer, with cost cuts kicking in, too. But when it comes to top-line results that topped analysts' forecasts, the company has its own hot sellers to thank.

Australia's CSL gets three Novartis vaccine plants in $275M deal

For $275 million, Australia's CSL is buying from Novartis a network of vaccine manufacturing facilities, as well as a portfolio of products.

Novartis chief Jimenez predicts 'multi-blockbuster' success for star heart drug

Novartis' pharma chief has hailed the company's forthcoming heart failure treatment as "the most exciting launch the company has ever had," and now the drugmaker's CEO has declared a "multi-blockbuster" in the making, joining a chorus of analysts who expect billions in annual sales from LCZ696.

Pharma's top 10 M&A deals of 2014's first half

Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of...

Novartis officially bows out of vaccines with flu sale to CSL

Novartis' 8-year foray into vaccines is officially coming to a close. After divesting the bulk of its unit to GlaxoSmithKline in an April deal, the pharma giant Sunday announced it had agreed to sell its flu shot business to Australia's CSL. And with that, it'll make its exit from a field that's given it trouble since its Chiron buyout in 2006.